|
|
Post by brentie on Sept 16, 2015 9:21:25 GMT -5
|
|
|
|
Post by compound26 on Sept 16, 2015 10:19:43 GMT -5
"According to recent prescription data, there are still under 500 Afrezza users in the country. Clearly, Afrezza sales will need to begin to acquire some momentum by the end of this year and into 2016."
Wondering if that 500 number is a typo. Since last week's TRx is 585 according to Symphony, a conservative estimate of the total Afrezza users would be 4 to 5 times of the TRx of the week, which means somewhere around 2,000 to 3,000 Afrezza users. Alternatively, 10-12 times of the weekly refills will yield a similar estimate. Based on the refills, I would estimate the current Afrezza users to be around 3,000 considering the effect of the samples and that many users have not started to refill yet. Wondering if Rob meant to say under 5,000 Afrezza users in the country.
|
|
|
|
Post by nylefty on Sept 16, 2015 11:56:30 GMT -5
"According to recent prescription data, there are still under 500 Afrezza users in the country. Clearly, Afrezza sales will need to begin to acquire some momentum by the end of this year and into 2016." Wondering if that 500 number is a typo. Since last week's TRx is 585 according to Symphony, a conservative estimate of the total Afrezza users would be 4 to 5 times of the TRx of the week, which means somewhere around 2,000 to 3,000 Afrezza users. Alternatively, 10-12 times of the weekly refills will yield a similar estimate. Based on the refills, I would estimate the current Afrezza users to be around 3,000 considering the effect of the samples and that many users have not started to refill yet. Wondering if Rob meant to say under 5,000 Afrezza users in the country. I've pointed out his mistake in the comments following his article, but he has yet to respond. Meanwhile, the bashers are loving it, since fewer than 500 users would mean that Afrezza would be a complete failure at this point. The bashers are also interpreting the article as saying that only 27 doctors have prescribed Afrezza. |
|
|
|
Post by compound26 on Sept 16, 2015 12:17:04 GMT -5
Additionally, even though there are only 75 physicians in Sam's list according to Rob. I would estimate the actual number of Afrezza prescribing physicians is more than that. I would guess somewhere between 100-200 in total.
|
|
|
|
Post by Chris-C on Sept 16, 2015 12:20:11 GMT -5
Yes. Unfortunate typo. It's not like the shorts need any additional ammunition. Now we're taking on casualties from friendly fire.  |
|
|
|
Post by roseylv on Sept 16, 2015 12:46:13 GMT -5
Why has Robert not acknowledged that it was in fact a typo? A few comments have been made about the issue and yet he is not responding....
|
|
|
|
Post by compound26 on Sept 16, 2015 12:51:21 GMT -5
Rob sent a PM to me. It was a typo. He has requested for correction to the editor.
|
|
|
|
Post by roseylv on Sept 16, 2015 13:12:51 GMT -5
It has been corrected to read "under 5,000".
Thanks compound!
|
|
|
|
Post by scottiemac on Sept 16, 2015 13:44:36 GMT -5
He's basing that number on Sam Finta's list, which is by no means complete.
|
|
|
|
Post by patryn on Sept 16, 2015 14:51:00 GMT -5
The number of disinterested observers posting on the article about just how little the stock price affects them and how much they just want to spread the truth leads me to believe that there is some serious money and anxiety on the line. Buy and hold for the long term and stop reading comments from people with agendas to live a more carefree life  |
|
|
|
Post by mssciguy on Sept 16, 2015 17:31:09 GMT -5
"New hire orientation" at MGM Grand via Stocktwits... completely unverified (full disclaimers apply) prntscr.com/8h5z2cBREAKOUT |
|
|
|
Post by mssciguy on Sept 16, 2015 17:33:37 GMT -5
"New hire orientation" at MGM Grand via Stocktwits... completely unverified (full disclaimers apply) prntscr.com/8h5z2cBREAKOUT "and now for the REST OF THE STORY" -- again, unverified prntscr.com/8h605y  |
|
|
|
Post by mssciguy on Sept 17, 2015 5:17:14 GMT -5
Success with insulin therapy however is equally dependent upon
its physiologic properties as its proper use by patients. Rapid acting insulin’s often fall short of physiologic
needs with delayed onset of action and prolonged effects leading to post-mealtime hyperglycemia and delayed hypoglycemia. Common barriers to subcutaneous insulin use include fear of hypoglycemia, number of injections, weight gain, and concerns regarding regimen complexity and flexibility. Injectable insulin’s do not address the barriers commonly associated with insulin, nor the desired physiologic rapid-on, rapid-off control of prandial hyperglycemia coupled with reduced rates of hypoglycemia. Alternative, less invasive routes of administration such as inhaled insulin may provide some of these pharmacologic improvements while eliminating certain patient barriers to insulin initiation, yet require robust healthcare practitioner instruction (e.g. patient eligibility, spirometry, unique dosing units/ conversion; concomitant utilization with other diabetes agents device utilization and periodic safety testing) to ensure appropriate product understanding and utilization in both type 1 and type 2 diabetes patients. ===================> namec-assn.org/Resources/Documents/RFP_DM__PL_YMCPM_%202015_Dex_FINAL.pdf Not sure what to think about this but it seems relevant enough to post. May be something in here too (the "rapid acting" insulins sound complicated) www.amcp.org/WorkArea/DownloadAsset.aspx?id=20165All via fofos2000 (Europe) , stocktwits |
|
|
|
Post by mssciguy on Sept 17, 2015 5:32:10 GMT -5
robsacher this is good too , via fofos2000 (stocktwits)--- must be a practitioner or insider, worth checking out, high relevance  Sponsored by: Sanofi Diabetes Update Jennifer Whaley, PharmD, BCPS; Senior Regional Medical Liaison; Sanofi Diabetes Presentation Objectives: • Briefly review the natural history of Type 2 DM • Briefly overview the 2015 ADA/EASD Position Statement on Antihyperglycemic Therapy in T2DM • Discuss the unmet need & clinical challenges associated with the initiation & intensification of insulin therapy • Review the pharmacology & clinical efficay & safety of two novel insulin therapies: o Insulin Glargine U300 (Toujeo®) o Inhaled Insulin (Afrezza®) c.ymcdn.com/sites/www.texasnp.org/resource/resmgr/Fall_Conference_2015/TNP_Conf_Brochure_2015.pdf
|
|
|
|
Post by peppy on Sept 17, 2015 6:24:10 GMT -5
robsacher this is good too , via fofos2000 (stocktwits)--- must be a practitioner or insider, worth checking out, high relevance Sponsored by: Sanofi Diabetes Update Jennifer Whaley, PharmD, BCPS; Senior Regional Medical Liaison; Sanofi Diabetes Presentation Objectives: • Briefly review the natural history of Type 2 DM • Briefly overview the 2015 ADA/EASD Position Statement on Antihyperglycemic Therapy in T2DM • Discuss the unmet need & clinical challenges associated with the initiation & intensification of insulin therapy • Review the pharmacology & clinical efficay & safety of two novel insulin therapies: o Insulin Glargine U300 (Toujeo®) o Inhaled Insulin (Afrezza®) c.ymcdn.com/sites/www.texasnp.org/resource/resmgr/Fall_Conference_2015/TNP_Conf_Brochure_2015.pdf Well done presentation of the documented information on Afrezza for Nursing! It was the first time I saw diabetic nerve damage included in the presenting information. I looked very complete to me. Go nursing.
|
|
